Australia's most trusted
source of pharma news
Posted 23 June 2025 AM
The PBAC was generous with recommendations for changes to listings in its May intracycle meeting, with one drug seeing a significantly expanded population and several others getting the nod for new indications.
Boehringer Ingelheim is celebrating an expanded population for Jardiance in treating adult patients with chronic kidney disease, in line with the population from the pivotal clinical trial, EMPA-KIDNEY. The recommendation was helped along by a recent 10-year F1 statutory price reduction on the PBS.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.